Albert Bourla

Albert Bourla

Personal details
Born	Albert Bourla 1961/10/21 (age 64) 🇬🇷 Thessaloniki, Greece
Nationality	🇬🇷 Greek 🇺🇸 American (naturalized)
Education	DVM, PhD Biotechnology
Spouse	Myriam Alchanati Bourla (married)
Children	2 (daughter Selise, son Mois)
Career details
Occupation	Pfizer Chairman & CEO
Compensation	$24.6 million (2024)
Net worth	~$40 million (est. 2023)

Albert Bourla (Άλμπερτ Μπουρλά; born 21 October 1961) is a Greek-American veterinarian and businessman serving as Chairman and Chief Executive Officer of Pfizer since January 2019, leading the pharmaceutical giant through the historic development of the first authorized COVID-19 vaccine in record time.

Born in Thessaloniki, Greece to Sephardic Jewish Holocaust survivor parents, Bourla trained as a veterinarian before joining Pfizer's animal health division in 1993 and rising through the ranks over 25 years to become CEO. His compensation reached $24.6 million in 2024 following a rebound year for Pfizer.

Under Bourla's leadership, Pfizer partnered with BioNTech to develop the first COVID-19 vaccine authorized in Western countries (November 2020), completing clinical trials in an unprecedented 8 months - a process that typically takes years. The achievement brought Pfizer $100 billion in revenue in 2022, more than double pre-pandemic levels, while earning Bourla Time Magazine's "Heroes of the Year" (2021) and the Genesis Prize ($1M donated to Holocaust education).

Early Life and Education

Born 21 October 1961 in Thessaloniki, Greece, to a Sephardic Jewish family of Holocaust survivors. His mother escaped a firing squad execution after capture during the Holocaust. He grew up in Thessaloniki, which he still considers the "epicenter of his life," and is known as "Akis" to family and friends in Greece.

Bourla studied veterinary medicine at Aristotle University of Thessaloniki, earning his DVM degree in 1985 and his PhD in biotechnology of reproduction in 1991. His doctoral thesis was titled "Effect of melatonin implants on sperm characteristics and on the freezability of Karagouniki ram semen." He began his career as a practicing veterinarian.

Personal Life

Bourla is married to Myriam Alchanati, originally from Greece. They have two children: daughter Selise, who has cerebral palsy, and son Mois, who attended college. His wife Myriam is devoted to ensuring Selise leads a thriving life. During the pandemic, Bourla would bounce ideas off his son Mois between calls with world leaders and scientists.

Bourla left Greece in 1995 at age 34 with his wife after a Pfizer promotion, living in seven cities across four countries before becoming a U.S. Citizen. The family resides in Scarsdale, New York. He maintains strong connections to Thessaloniki and visits Yad Vashem with his wife for Holocaust remembrance, honoring his family's survival.

Career

Early Pfizer Career (1993-2010)

Bourla joined Pfizer in 1993 as a doctor of veterinary medicine and technical director for the animal health division in Greece. He rose through various positions in animal health across Europe. He left Greece at age 34 in 1995 after a promotion, relocating with his wife Myriam. He lived in seven cities across four countries during his Pfizer career and immigrated to the United States in 2001.

Executive Rise (2010-2019)

Bourla served various executive roles including Chief Operating Officer of Pfizer's Animal Health division. He held leadership positions across multiple geographies and business units. In January 2019, he was appointed CEO of Pfizer, succeeding Ian Read.

COVID-19 Vaccine Development (2020-2021)

In March 2020, Bourla partnered with BioNTech, led by Turkish-German scientists Ugur Sahin and Ozlem Tureci, for COVID-19 vaccine development. Bourla set an "impossible" goal: complete vaccine trials in 8 months (typical vaccine development takes years). In November 2020, the Pfizer-BioNTech vaccine became the first COVID-19 vaccine authorized in Western countries. In December 2020, the FDA granted emergency use authorization. The vaccine became the most administered COVID vaccine globally, with 3.5 billion doses delivered by the end of 2021.

Recent Leadership (2022-Present)

In 2022, Pfizer revenue reached $100 billion, more than double from two years prior. In 2023, revenue plummeted as COVID vaccine demand collapsed, and the stock lost half its value from its 2021 peak. In October 2024, activist hedge fund Starboard Value took a $1 billion stake demanding changes. Bourla defended his leadership amid investor pressure.

Compensation

Bourla's 2024 total compensation was $24.6 million (14% increase):

• $8.82 million cash
• $14.83 million equity
• $996,000 pension/other

He received a $7 million incentive award in 2024 (nearly double the $3.6 million target). In 2022, when COVID products peaked, he earned $33 million. In 2023, his compensation dropped 35% to $21.6 million after misjudging plummeting vaccine demand. His net worth is estimated at approximately $40 million (2023), mostly in Pfizer stock (123,055+ units valued at $11.7M+ as of March 2022).

Awards and Recognition

• Time Magazine "Heroes of the Year" (2021) for vaccine development
• Genesis Prize 2022 ($1 million donated to Holocaust education initiatives)

However, former CDC chief Tom Frieden criticized Bourla's pandemic pricing as engaging in "war profiteering."

Controversies

Vaccine Price Gouging Allegations

In December 2022, Senator Elizabeth Warren wrote to Bourla accusing Pfizer of "pure and deadly greed" over plans to charge up to $130 per dose - quadruple the previous price and a 10,000% markup over estimated production costs. The price increase was projected to bring Pfizer an additional $2.5-3 billion in annual revenue. Former CDC director Tom Frieden called the pricing strategy "war profiteering." Warren warned the price could result in "COVID-induced fatalities of many uninsured Americans."

Republican Political Attacks

In May 2025, Rep. Jim Jordan (House Judiciary Committee) sent a letter alleging "three most senior people in Pfizer R&D were involved in decision to deliberately slow down clinical testing so it would not be complete prior to results of presidential election" in late 2020. Pfizer denied the allegations.

Stock Performance and Activist Pressure

In October 2024, hedge fund Starboard Value took a $1 billion stake in Pfizer seeking changes, as the stock had lost half its value since the 2021 peak. A Yale analysis defended Bourla's leadership, noting activist critics missed facts about pandemic response complexity.

BBC Interview Ethics Violation

In 2021, the British Medical ethics Authority determined Pfizer violated an ethical code following a BBC interview by Bourla, finding the company guilty of "misleading the public, making unsubstantiated claims, and failing to present information in factual and balanced way."

Vaccine Misinformation Comments

In November 2021, Bourla called people spreading vaccine misinformation "criminals," sparking controversy from vaccine skeptics and free speech advocates.